Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 12, 2007

Primary Completion Date

July 29, 2011

Study Completion Date

July 29, 2011

Conditions
LymphomaMultiple Myeloma and Plasma Cell NeoplasmSmall Intestine Cancer
Interventions
BIOLOGICAL

Streptococcus pneumoniae

Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)

OTHER

laboratory correlative studies

Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.

OTHER

quality-of-life assessment

Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00569309 - Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma | Biotech Hunter | Biotech Hunter